^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | bintrafusp alfa (M7824) (PD-L1 inhibitor, TGFβ inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy
Published date:
01/11/2021
Excerpt:
In this phase II study (NCT03436563), pts with MSI-H metastatic solid tumors who had progressed on prior ICB were eligible. Pts received 1200 mg BA intravenously every 14 days. Dual inhibition of TGF-ß and PD-L1 by BA did not demonstrate significant anti-tumor activity in the majority of pts with MSI-H metastatic cancer who had progressed on prior ICB.
Trial ID:
